Last reviewed · How we verify
Stroke — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tryvio | APROCITENTAN | Idorsia | Endothelin Receptor Antagonist [EPC] | 2025-01-01 | ||
| Lisinopril/HCTZ | HCTZ | Direct_Rx | Thiazide Diuretic [EPC] |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Direct_Rx · 1 drug in Stroke
- Idorsia · 1 drug in Stroke
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Stroke:
Cite this brief
Drug Landscape (2026). Stroke — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/stroke. Accessed 2026-06-10.
Related
- Stroke full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing